AstraZeneca Pharma India is planning to sell its 64-acre property in Bengaluru as part of a broader land monetization strategy. The sale is expected to generate ₹3,400 crore (approximately $410 million) for the company.
Several developers, including the Sattva Group, Aurobindo Pharma, and RMZ, have expressed interest in acquiring the land parcel, according to sources familiar with the deal. The potential sale reflects a strategic move by AstraZeneca to optimize its assets and capital allocation in India.
The deal underscores ongoing investment and development activity in Bengaluru’s real estate market, driven by demand for commercial and residential space. AstraZeneca’s decision to monetize its land holdings aligns with a trend among multinational corporations to unlock value from non-core assets.
The proceeds from the sale are expected to be reinvested into AstraZeneca’s core pharmaceutical operations, supporting research, development, and manufacturing activities in India.